Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 397

1.

2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan.

Li YH, Fang CY, Hsieh IC, Huang WC, Lin TH, Sung SH, Chiu CZ, Wu CJ, Shyu KG, Chang PY, Fang CC, Lu TM, Chen CP, Tai WC, Sheu CC, Wei KC, Huang YH, Wu HM, Hwang JH.

Acta Cardiol Sin. 2018 May;34(3):201-210. doi: 10.6515/ACS.201805_34(3).20180302A. Review.

2.

Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?

Zeb I, Krim N, Bella J.

Expert Rev Cardiovasc Ther. 2018 May;16(5):369-377. doi: 10.1080/14779072.2018.1459186. Epub 2018 Apr 3. Review.

PMID:
29589775
3.

Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.

Danielak D, Karaźniewicz-Łada M, Główka F.

Expert Opin Pharmacother. 2018 Feb;19(2):103-112. doi: 10.1080/14656566.2017.1421634. Epub 2017 Dec 27. Review.

PMID:
29280403
4.

Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.

Tarantini G, Ueshima D, D'Amico G, Masiero G, Musumeci G, Stone GW, Brener SJ.

Am Heart J. 2018 Jan;195:78-85. doi: 10.1016/j.ahj.2017.09.012. Epub 2017 Sep 21. Review.

PMID:
29224649
5.

Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.

Khan SU, Arshad A, Riaz IB, Talluri S, Nasir F, Kaluski E.

Am J Cardiol. 2018 Feb 1;121(3):301-307. doi: 10.1016/j.amjcard.2017.10.035. Epub 2017 Oct 31. Review.

PMID:
29195825
6.

Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review.

Fake A, Ranchord A, Harding S, Larsen P.

Curr Cardiol Rev. 2017;13(4):325-333. doi: 10.2174/1573403X13666170927121808. Review.

PMID:
28969538
7.

[Risk of fatal/non-fatal events in patients with previous coronary heart disease/acute myocardial infarction and treatment with non-steroidal anti-inflammatory drugs].

Muñoz Olmo L, Juan Armas J, Gomariz García JJ.

Semergen. 2018 Jul - Aug;44(5):355-363. doi: 10.1016/j.semerg.2017.07.004. Epub 2017 Sep 4. Review. Spanish.

PMID:
28882733
8.

Update on antithrombotic therapy after percutaneous coronary revascularisation.

Cuisset T, Verheugt FWA, Mauri L.

Lancet. 2017 Aug 19;390(10096):810-820. doi: 10.1016/S0140-6736(17)31936-0. Review.

PMID:
28831996
9.

Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.

Dhanrajani A, Yeung RSM.

Curr Opin Rheumatol. 2017 Sep;29(5):547-552. doi: 10.1097/BOR.0000000000000425. Review.

PMID:
28661936
10.

Platelet pathophysiology, pharmacology, and function in coronary artery disease.

Ibrahim H, Kleiman NS.

Coron Artery Dis. 2017 Nov;28(7):614-623. doi: 10.1097/MCA.0000000000000519. Review.

PMID:
28644213
11.

Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review.

Sumner JD, Zinser B, Smith A.

J Pharm Pract. 2018 Jun;31(3):335-341. doi: 10.1177/0897190017715560. Epub 2017 Jun 20. Review.

PMID:
28629303
12.

Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.

Lettino M, Leonardi S, De Maria E, Halvorsen S.

Eur J Prev Cardiol. 2017 Jun;24(3_suppl):61-70. doi: 10.1177/2047487317707854. Review.

PMID:
28618904
13.

von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review.

Morici N, Cantoni S, Panzeri F, Sacco A, Rusconi C, Stucchi M, Oliva F, Cattaneo M.

Thromb Res. 2017 Jul;155:78-85. doi: 10.1016/j.thromres.2017.05.011. Epub 2017 May 12. Review.

PMID:
28521259
14.

Antiplatelet treatments: recent evidence from randomized controlled trials.

Vogel B, Baber U.

Curr Opin Cardiol. 2017 Jul;32(4):356-362. doi: 10.1097/HCO.0000000000000416. Review.

PMID:
28463894
15.

Cangrelor: A New Route for P2Y12 Inhibition.

Sible AM, Nawarskas JJ.

Cardiol Rev. 2017 May/Jun;25(3):133-139. doi: 10.1097/CRD.0000000000000142. Review.

PMID:
28379902
16.

Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.

Villablanca PA, Holmes D Jr, Mohananey D, Briceno DF, Núñez Gil IJ, Kargoli F, Gupta T, Kizer JR, Bortnick AE, Wiley J, Menegus MA, Pyo R, García M, Ramakrishna H, Mookadam F.

Coron Artery Dis. 2017 Aug;28(5):395-405. doi: 10.1097/MCA.0000000000000485. Review.

PMID:
28328784
17.

[Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept].

Silber S.

MMW Fortschr Med. 2017 Mar;159(5):49-52. doi: 10.1007/s15006-017-9389-8. Review. German. No abstract available.

PMID:
28321726
18.

Duration of dual antiplatelet therapy in acute coronary syndrome.

Wilson SJ, Newby DE, Dawson D, Irving J, Berry C.

Heart. 2017 Apr;103(8):573-580. doi: 10.1136/heartjnl-2016-309871. Epub 2017 Mar 1. Review.

19.

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.

Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW.

Eur Heart J. 2017 Apr 7;38(14):1034-1043. doi: 10.1093/eurheartj/ehw627. Review.

20.

A Review of the Clinical Utility of Intravascular Ultrasound and Optical Coherence Tomography in the Assessment and Treatment of Coronary Artery Disease.

Matthews SD, Frishman WH.

Cardiol Rev. 2017 Mar/Apr;25(2):68-76. doi: 10.1097/CRD.0000000000000128. Review.

PMID:
28099219

Supplemental Content

Loading ...
Support Center